Adjuvant treatment with vitamin D in tuberculosis
Phase 2
- Conditions
- Tuberculosis.Tuberculosis of lung,confirmed by sputum microscopy with or without cultureA-15.o
- Registration Number
- IRCT201407029855N5
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
patients with smear positive pulmonary tuberculosis; younger than 15 years for entry into the study; obtain informed consent
Exclusion criteria: Patients who have medical complications during the follow-up study; patients who need to change during the study medication are routine tuberculosis; Patients who are suffering from systemic disease or other debilitating (Such as chronic liver disease, kidney disease, HIV, Malignancy etc); patients who have recently used of vitamin D in any other reason; Patients taking vitamin D in the past have suffered side effects or drug allergy; Pregnancy; in patients who taking of vitamin D is prohibited
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Erythrocyte Sedimentation Rate. Timepoint: Weeks of 2,4,6,8. Method of measurement: With westergren method - millimeters per first hour.;C-Reactive Protein. Timepoint: Weeks of 2,4,6,8. Method of measurement: Latex method - 1+ to 4+.;Complete Blood Count. Timepoint: Weeks of 2,4,6,8. Method of measurement: Measurment of Hgb and WBC.;Improvement of patient's symptoms. Timepoint: Weeks of 2,4,6,8. Method of measurement: Check list.
- Secondary Outcome Measures
Name Time Method Improved quality of life. Timepoint: Day 0 and day 30 of treatment. Method of measurement: SF-12 questionnaire.